Rxsight, Inc. Stock Price, News & Analysis

RxSight, Inc. (NASDAQ: RXST) has announced a priced public offering of 4,000,000 shares of common stock at $12.50 each, aiming to raise approximately $50 million. The company has also granted underwriters a 30-day option to purchase an additional 600,000 shares. Proceeds will be directed towards commercial and marketing expansion, product development, research, and working capital needs. The offering is expected to close around February 10, 2023, subject to customary conditions. BofA Securities serves as the sole bookrunning manager for this public offering.

RxSight, Inc. (NASDAQ: RXST) announced plans for a public offering of $40 million in common stock. The company may grant underwriters a 30-day option to purchase an additional 15% of shares. Proceeds will fund commercial and marketing expansion, product development, and working capital. The offering will occur under a previously filed shelf registration statement. However, completion of the offering is subject to market conditions and cannot be guaranteed.

RxSight is focused on enhancing post-cataract surgery vision with its Light Adjustable Lens system, which allows customization of visual acuity.

RxSight, Inc. (NASDAQ: RXST) reported preliminary unaudited financial results for Q4 and full-year 2022. Q4 revenue is projected at $16.1 million, a 91% increase year-over-year, driven by sales of 57 Light Delivery Devices (LDDs) and 9,123 Light Adjustable Lenses (LALs). For the full year, revenue is expected to be $49.0 million, marking a 117% growth. The company's cash and equivalents were about $105.8 million at year-end. The final audited results will be announced in early March 2023.

RxSight, Inc. (NASDAQ: RXST) has announced its participation in the J.P. Morgan Healthcare Conference, scheduled for January 11, 2023, at 11:15 a.m. PT. This event focuses on enhancing vision for cataract surgery patients through innovative technologies. RxSight's Light Adjustable Lens system is the first customizable intraocular lens technology aimed at optimizing post-surgery visual acuity. Interested parties can access the live and archived webcast via this link.

RxSight, Inc. reported Q3 2022 revenue of $12.6 million, marking a 118% increase year-over-year. Key drivers included 49 Light Delivery Devices sold, a 58% unit increase, and 6,595 Light Adjustable Lenses, up 234% in procedures. The company raised its full-year revenue guidance to $47.0 million - $48.0 million, indicating a growth of 108% - 112%. However, operational costs rose by 47.5%, leading to a net loss of $(16.8) million.

RxSight, Inc. (NASDAQ: RXST), an ophthalmic medical device company, will announce its third quarter 2022 financial results on November 7, 2022, after market close. Management will host a conference call at 1:30 p.m. PT to discuss the results. The company is known for its innovative RxSight Light Adjustable Lens system that allows customization of visual acuity post-cataract surgery. This advanced technology is the first of its kind in the intraocular lens market.

RxSight, Inc. (NASDAQ: RXST), a medical device company focused on enhancing vision post-cataract surgery, will participate in the Wells Fargo Healthcare Conference on September 8, 2022, at 8:35 a.m. PT / 11:35 a.m. ET. The event will feature a fireside chat with management, and interested parties can access a live and archived webcast through their investor relations website.

RxSight specializes in innovative lens technology, including the RxSight Light Adjustable Lens system, which allows doctors to tailor visual acuity for patients after cataract procedures.

RxSight, Inc. (NASDAQ: RXST) has filed a $200 million shelf registration statement with the SEC, allowing it to sell various securities including common and preferred stock. This strategy aims to provide flexibility in accessing capital under favorable market conditions. Specifically, the company also intends to offer up to $50 million of common stock through an at-the-market (ATM) offering, managed by BofA Securities. The registration is pending effectiveness, and the company emphasizes the importance of reviewing the prospectus for potential investment risks.

RxSight, Inc. reported significant financial growth for Q2 2022, with revenues of $11.4 million, marking a 132% increase year-over-year. The company's sales included 49 Light Delivery Devices (LDDs), a 96% increase, and 5,400 Light Adjustable Lenses (LALs), representing a 196% rise in procedures. Full-year revenue guidance is now set at $44.0 to $46.0 million, indicating a growth rate of 95% to 104% compared to 2021. Despite a net loss of $(16.7) million, the company is seeing robust demand for its products.